Seeking Alpha

OncoMed reports its first quarterly results since its July IPO; net losses widen

  • OncoMed (OMED +1.5%) moves up after reporting its first results since going public in July.
  • Q2 net losses widened to $9.6M from $3.8M for the year ago period, mainly because of the timing of a $5M milestone payment in the same quarter last year.
  • Collaboration revenues declined to $2.9M, compared to $7.5M for Q212.
  • The company received a $10M milestone payment in August, related to the Phase I dose escalation in its vantictumab program, part of its collaboration with Bayer Pharma AG.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|